SBMU, Pharmaceutical Research Sciences
  • Register
  • Login
International Pharmacy Acta
  • Home
  • Journal Info
    • About
    • Aim and Scope
    • Ownership & Management
    • Indexing
    • Editorial Team
  • New Submission
  • Author Guidelines
    • Guideline
    • Types of articles
    • Templates
    • Publication Fees
  • Policies and Process
    • Publication Policy
    • Peer Review Process
    • Open Access Policy
    • plagiarism
    • Archiving
    • Privacy Statement
    • Copyright Notice
    • Waiver policy
    • Complaints Policy
    • Post- Publication Discussions and Corrections Policy
    • Advertisement and Marketing
  • Issues
    • Current
    • Archives
  • Contact us
Advanced Search
  1. Home
  2. Archives
  3. Vol. 1 No. 1 (2018): Pharmacy Updates 2018 (Congress Proceeding)
  4. Supplementary Issues: Reviews of books, journal, congress, other media Special issues, and Scientific news

Vol. 1 No. 1 (2018)

March 2018

Construction of recombinant vector harboring gene encoding scFv against EpEX and Pichia pastoris transformant isolation

  • Fatemeh Mohammad Gholizad
  • Farideh Rasooli
  • Atieh Hashemi

International Pharmacy Acta, Vol. 1 No. 1 (2018), 4 March 2018 , Page 80-81
https://doi.org/10.22037/ipa.v1i1.20511 Published: 2018-03-04

  • View Article
  • Download
  • Cite
  • Statastics
  • Share

Abstract

Introduction

As a transmembrane glycoprotein, the epithelial cell adhesion molecule (EpCAM) has been shown to be strongly overexpressed on the majority of tumor cells of epithelial origin and its overexpression has been supposed to support tumor progression and metastasis. Hence EpCAM has been made as a suitable antigen for targeted cancer therapy. In this case different types of antibodies including antibody fragments such as single chain fragment variable (ScFv) antibodies have been produced for drug delivery to this specific antigen. Pichia pastoris is a highly efficient and cost-effective system for expression of recombinant proteins. In this study, we used the Pichia expression system to express a ScFv against EpCAM extracellular domain (EpEX).

Materials and Methods: A codon optimized gene encoding anti-EpEX protein was cloned into the XhoI and XbaI sites of the pPICZαB vector. Transformation of CS115 strain was performed via electroporation method. The recombinant protein was linearized by using SacI restriction endonuclease prior to gene integration into the genome.

Results: Successfully cloned anti- EpEX gene into the pPICZαB vector was confirmed by restriction analysis and sequencing. The transforming agents with genome containing inserted pPICZαB- anti- EpEX were confirmed via PCR amplification of genomic DNA using AOX1 primers.

Conclusion: These findings imply that the engineered strain is able to express the recombinant anti- EpEX which may be used as a potential candidate in cancer immunotherapy.

 

Keywords:
  • EpCAM, Recombinant protein, ScFv, pPICZαB, Pichia pastoris, CS115
  • PDF

How to Cite

Mohammad Gholizad, F., Rasooli, F., & Hashemi, A. (2018). Construction of recombinant vector harboring gene encoding scFv against EpEX and Pichia pastoris transformant isolation. International Pharmacy Acta, 1(1), 80–81. https://doi.org/10.22037/ipa.v1i1.20511
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
  • Abstract Viewed: 261 times
  • PDF Downloaded: 183 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Information

  • For Readers
  • For Authors
  • For Librarians

Make a Submission

Make a Submission
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

Creative Commons License
This journal (and its contents) is licensed under a  Creative Commons Attribution-NonCommercial 4.0 International License.

 

                                                  Online ISSN: 2645-3266

                                                  Print ISSN: 2645-3258                                                 

Powered by OJSPlus